Management of Hyperglycemia in Post-Stroke Diabetic Patients

Rationale for Active Glucose Management

The American Heart Association/American Stroke Association guidelines recommend treating elevated glucose concentrations in the range of 140-180 mg/dL, as persistent hyperglycemia (>200 mg/dL) during the first 24 hours independently predicts expansion of infarct volume and worse outcomes 1, 2, 3, 4
Hyperglycemia increases tissue acidosis through anaerobic glycolysis, promotes free radical production, affects the blood-brain barrier, increases brain edema risk, and is associated with hemorrhagic transformation of the infarction 3, 5

The American Diabetes Association recommends initiating subcutaneous insulin therapy, targeting a glucose range of 140-180 mg/dL to balance efficacy with hypoglycemia risk in elderly patients 6, 7, 4
A basal-bolus insulin regimen is recommended, starting at 0.3 units/kg/day total daily dose, divided as half basal insulin once daily and half rapid-acting insulin before meals if oral intake is adequate 6

The American Geriatrics Society recommends monitoring glucose every 6 hours initially, and checking potassium levels before and during insulin therapy to avoid hypokalemia 4
Avoiding glucose levels <80 mg/dL is crucial, as hypoglycemia may be more immediately dangerous than moderate hyperglycemia, particularly in elderly patients with diabetes who are at increased risk of severe hypoglycemic events 7, 8, 4

The American Diabetes Association advises against using sliding-scale insulin alone as the single regimen, as it results in undesirable hypoglycemia and hyperglycemia and increased risk of hospital complications 6
The Journal of the American Geriatrics Society recommends avoiding chlorpropamide if considering oral agents, as it has a prolonged half-life in elderly patients and increases hypoglycemia risk 8

The American Geriatrics Society explicitly contraindicates chlorpropamide in older adults due to its prolonged half-life and escalating hypoglycemia risk with age, and sulfonylureas, particularly glyburide and chlorpropamide, should be avoided in older adults due to their high risk of prolonged hypoglycemia, as recommended by the Journal of the American Geriatrics Society 9

For relatively healthy older adults with good functional status, a target A1C of 7% or lower is reasonable, but for those with multiple comorbidities like this patient, a less stringent target such as 8% is appropriate to avoid hypoglycemia risks that outweigh benefits, according to the Journal of the American Geriatrics Society 9